Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Celularity, Inc. (CELU : NSDQ)

• Company Description    Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK. Number of Employees: 225

• Price / Volume Information    Yesterday's Closing Price: $7.46 Daily Weekly Monthly 20 Day Moving Average: 486,406 shares Shares Outstanding: 137.72 (millions) Market Capitalization: $1,027.40 (millions) Beta: -0.40 52 Week High: $13.40 52 Week Low: $3.63 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -37.15% -29.22% 12 Week 15.30% 26.75% Year To Date 45.70% 81.13%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 170 PARK AVE - FLORHAM PARK,NJ 07932 USA ph: 908-768-2170 fax: - None http://www.celularity.com

• General Corporate Information    Officers Robert J. Hariri - Chief Executive Officer and Chairman Andrew L. Pecora - President David C. Beers - Chief Financial Officer John Sculley - Director Jay R. Bloom - Director Peer Information Celularity, Inc. (CORR.) Celularity, Inc. (RSPI) Celularity, Inc. (CGXP) Celularity, Inc. (BGEN) Celularity, Inc. (GTBP) Celularity, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 151190105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 137.72 Most Recent Split Date: (:1) Beta: -0.40 Market Capitalization: $1,027.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 11.43 Price/Cash Flow: - Price / Sales: 41.75 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -1,500.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 22.19% ROE 03/31/22 - -136.80 12/31/21 - 71.61 09/30/21 - - ROA 03/31/22 - -22.86 12/31/21 - 6.07 09/30/21 - -40.83 Current Ratio 03/31/22 - 2.91 12/31/21 - 2.25 09/30/21 - 3.12 Quick Ratio 03/31/22 - - 12/31/21 - 1.89 09/30/21 - 2.93 Operating Margin 03/31/22 - -330.93 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - -330.93 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -330.85 12/31/21 - -469.17 09/30/21 - -324.46 Book Value 03/31/22 - 0.65 12/31/21 - 0.80 09/30/21 - 0.78 Inventory Turnover 03/31/22 - 1.66 12/31/21 - 2.52 09/30/21 - 2.59 Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.28 09/30/21 - 0.29 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 22.03 09/30/21 - 22.56

Powered by Zacks Investment Research ©